
Andrew T Lenis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2114123/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naA ⁻ ve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study. European Urology Oncology, 2022, 5, 544-552.	2.6	16
2	Does Artificial Intelligence Meaningfully Enhance Cystoscopy?. Journal of the National Cancer Institute, 2022, 114, 174-175.	3.0	3
3	Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype. JCO Precision Oncology, 2022, , .	1.5	6
4	Primary Robot-assisted Retroperitoneal Lymph Node Dissection for Men with Nonseminomatous Germ Cell Tumor: Experience from a Multi-institutional Cohort. European Urology Focus, 2021, 7, 1403-1408.	1.6	8
5	Trends in management of ureteral urothelial carcinoma and effects on survival: a hospital-based registry study. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 194.e17-194.e24.	0.8	7
6	Peripherally Acting μ-Opioid Receptor Antagonists in the Management of Postoperative Ileus: a Clinical Review. Journal of Gastrointestinal Surgery, 2021, 25, 293-302.	0.9	19
7	Relationship Between Mobile Digital Sensor Monitoring and Perioperative Outcomes: Systematic Review. JMIR Perioperative Medicine, 2021, 4, e21571.	0.3	2
8	Molecular classification and diagnostics of upper urinary tract urothelial carcinoma. Cancer Cell, 2021, 39, 793-809.e8.	7.7	65
9	When is a Seminoma not a Seminoma? The Incidence, Risk Factors and Management of Patients With Testicular Seminoma With Discordant Elevated Serum Alpha-fetoprotein. Urology, 2021, , .	0.5	0
10	The role of neoadjuvant chemotherapy, lymph node dissection, and treatment delay in patients with muscle-invasive bladder cancer undergoing partial cystectomy. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 496.e17-496.e24.	0.8	5
11	Sequencing of Renal Mass Biopsy and Ablation: Results from the National Cancer Database. Urology Practice, 2021, 8, 555-564.	0.2	0
12	Risk factors for penile fracture compared with a surgical control cohort in the United States: the role of substance abuse. Asian Journal of Andrology, 2021, 23, 236.	0.8	1
13	Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic Testing. European Urology Oncology, 2021, 4, 993-1000.	2.6	16
14	Positive surgical margins at radical prostatectomy in the United States: Institutional variations and predictive factors. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 1.e17-1.e23.	0.8	7
15	Bladder Cancer. JAMA - Journal of the American Medical Association, 2020, 324, 1980.	3.8	817
16	Sodium Fluorescein for Identification of Intraoperative Urine Leaks During Partial Nephrectomy. Urology, 2020, 142, 249.	0.5	3
17	Trends in palliative care interventions among patients with advanced bladder, prostate, or kidney cancer: A retrospective cohort study. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 854.e1-854.e9.	0.8	4
18	The association between N-methylnaltrexone, a peripherally acting mu-opioid receptor antagonist, and clinical outcomes in patients undergoing robotic-assisted radical cystectomy. World Journal of Urology, 2020, 38, 3113-3119.	1.2	5

ANDREW T LENIS

#	Article	IF	CITATIONS
19	Predictors of adequate lymph node dissection in patients with non–muscle invasive bladder cancer undergoing radical cystectomy and effect on survival. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 796.e7-796.e14.	0.8	7
20	The Role of Opioids and Their Receptors in Urological Malignancy: A Review. Journal of Urology, 2020, 204, 1150-1159.	0.2	14
21	MP12-02 INPATIENT PALLIATIVE CARE UTILIZATION IN UROLOGIC MALIGNANCY. Journal of Urology, 2020, 203	, 0.2	0
22	Urinary Diversion. JAMA - Journal of the American Medical Association, 2020, 324, 2222.	3.8	4
23	Analysis of guideline recommended use of renal mass biopsy and association with treatment. Canadian Journal of Urology, 2020, 27, 10285-10293.	0.0	0
24	Predicting Short-term Outcomes After Radical Cystectomy Based on Frailty. Urology, 2019, 133, 25-33.	0.5	24
25	Editorial Comment. Urology, 2019, 127, 47-48.	0.5	0
26	Second primary lung cancer in United States Cancer Survivors, 1992–2008. Cancer Causes and Control, 2019, 30, 465-475.	0.8	34
27	Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma and venous thrombus—Trends and effect on overall survival. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 577.e9-577.e16.	0.8	17
28	Variation in surgical treatment patterns for patients with prostate cancer in the United States: Do patients in academic hospitals fare better?. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 63-70.	0.8	3
29	Treatment utilization and overall survival in patients receiving radical nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma: evaluation of updated treatment guidelines. World Journal of Urology, 2019, 37, 1157-1164.	1.2	14
30	Editorial Comment. Journal of Urology, 2019, 202, 1134-1135.	0.2	0
31	Intravesical Therapy for Non-muscle Invasive Bladder Cancer-Current and Future Options in the Age of Bacillus Calmette-Guerin Shortage. Reviews in Urology, 2019, 21, 145-153.	0.9	9
32	Trends in urinary diversion after radical cystectomy for urothelial carcinoma. World Journal of Urology, 2018, 36, 409-416.	1.2	18
33	Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials. Journal of Urology, 2018, 199, 43-52.	0.2	37
34	Association between Metabolic Syndrome and Recurrence of Nonmuscle Invasive Bladder Cancer following bacillus Calmette-Guérin Treatment. Urology Practice, 2018, 5, 132-138.	0.2	16
35	Role of surgical approach on lymph node dissection yield and survival in patients with upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 9.e1-9.e9.	0.8	37
36	Overall survival in patients with metastatic renal cell carcinoma and clinical N1 disease undergoing cytoreductive nephrectomy and lymph node dissection. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 79.e19-79.e26.	0.8	5

ANDREW T LENIS

#	Article	IF	CITATIONS
37	Trends in usage of cytoreductive partial nephrectomy and effect on overall survival in patients with metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 78.e21-78.e28.	0.8	15
38	Association between renal mass biopsy and upstaging to perinephric fat involvement in a contemporary cohort of patients with clinical T1a renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 527.e13-527.e19.	0.8	18
39	Continuous saline bladder irrigation for two hours following transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer does not prevent recurrence or progression compared with intravesical Mitomycin-C. BMC Urology, 2018, 18, 93.	0.6	9
40	Overall survival in patients with residual disease after radical cystectomy and neoadjuvant chemotherapy. World Journal of Urology, 2018, 36, 1825-1833.	1.2	4
41	MP28-09 CYTOREDUCTIVE NEPHRECTOMY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA AND TUMOR THROMBUS – TRENDS AND EFFECT ON OVERALL SURVIVAL. Journal of Urology, 2018, 199, .	0.2	Ο
42	Serial retrograde instillations of sustained release formulation of mitomycin C to the upper urinary tract of the Yorkshire swine using a thermosensitive polymer: Safety and feasibility. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 272-278.	0.8	20
43	Regionalization of Cystectomy: Importance of Care Coordination, Bundled Payments and Surgical Ownership. Journal of Urology, 2017, 197, 278-279.	0.2	0
44	A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 39.e1-39.e7.	0.8	34
45	Effect of Pregnancy and Delivery on Cytokine Expression in a Mouse Model of Pelvic Organ Prolapse. Female Pelvic Medicine and Reconstructive Surgery, 2017, 23, 449-456.	0.6	5
46	PD19-10 THE CHEMOABLATIVE EFFECT OF VESIGEL INSTILLATION IN PATIENTS WITH NMIBC – RESPONSE RATE AND 1-YEAR DURABILITY. Journal of Urology, 2017, 197, .	0.2	4
47	MP98-05 CHECKPOINT INHIBITION WITH SYSTEMIC ANTI-PROGRAMMED CELL DEATH LIGAND-1 AND INTRAVESICAL TMX-101 DECREASE TUMOR BURDEN INÂA MOUSE MODEL OF UROTHELIAL CARCINOMA. Journal of Urology, 2017, 197, .	0.2	Ο
48	PD73-01 RENAL MASS BIOPSY IS ASSOCIATED WITH INCREASED INCIDENCE OF PATHOLOGICAL UPSTAGING TO PERINEPHRIC FAT INVASION IN PATIENTS WITH CLINICALLY LOCALIZED RENAL CELL CARCINOMA. Journal of Urology, 2017, 197, .	0.2	0
49	MP22-16 CYTOREDUCTIVE PARTIAL NEPHRECTOMY FOR SMALL PRIMARY TUMORS IMPROVES OVERALL SURVIVAL IN METASTATIC KIDNEY CANCER. Journal of Urology, 2017, 197, .	0.2	0
50	Sustained-release Formulation of Mitomycin C to the Upper Urinary Tract Using a Thermosensitive Polymer: A Preclinical Study. Urology, 2017, 99, 270-277.	0.5	31
51	Immunotherapy for the Treatment of Urothelial Carcinoma. Journal of Urology, 2017, 197, 14-22.	0.2	87
52	Ablative Therapies for Early Stage Kidney Cancer and the Evolving Role of the Urologist. Urology Practice, 2017, 4, 162-168.	0.2	0
53	Association Between Number of Endoscopic Resections and Utilization of Bacillus Calmette-Guérin Therapy for Patients WithÂHigh-Grade, Non–Muscle-Invasive BladderÂCancer. Clinical Genitourinary Cancer, 2017, 15, e25-e31.	0.9	16
54	Second primary lung cancer in the United States: 1992–2008 Journal of Clinical Oncology, 2017, 35, 309-309.	0.8	0

ANDREW T LENIS

#	Article	IF	CITATIONS
55	MP01-19 UTILIZATION PATTERNS OF INTRAVESICAL BACILLUS CALMETTE-GUERIN THERAPY FOR PATIENTS WITH HIGH-GRADE, NON-MUSCLE INVASIVE BLADDER CANCER. Journal of Urology, 2016, 195, .	0.2	0
56	MP70-07 NATIONAL PRACTICE PATTERNS AND OUTCOMES OF ABLATIVE TECHNIQUES USED TO TREAT PATIENTS WITH STAGE I KIDNEY CANCER. Journal of Urology, 2015, 193, .	0.2	0
57	From the genomic frontier to immunotherapeutics. Nature Reviews Urology, 2015, 12, 74-76.	1.9	4
58	Testosterone Replacement Therapy in Men with Prostate Cancer: A Time-Varying Analysis. Journal of Sexual Medicine, 2015, 12, 374-380.	0.3	18
59	Validation of Genetically Matched Wild-Type Strain and Lysyl Oxidase–Like 1 Knockout Mouse Model of Pelvic Organ Prolapse. Female Pelvic Medicine and Reconstructive Surgery, 2014, 20, 287-292.	0.6	17
60	Cryoablation Versus Minimally Invasive Partial Nephrectomy for Small Renal Masses in the Solitary Kidney: Impact of Approach on Functional Outcomes. Journal of Urology, 2013, 189, 818-822.	0.2	28
61	Patterns of Hardware Related Electrode Failures in Sacral Nerve Stimulation Devices. Journal of Urology, 2013, 190, 175-179.	0.2	14
62	124 PATHOPHYSIOLOGIC CHANGES IN LOXL-1 KNOCKOUT MOUSE WITH PELVIC FLOOR DYSFUNCTION INDUCE A COMPENSATORY AND ABERRANT ELASTIN REGENERATIVE RESPONSE BY VAGINAL SMOOTH MUSCLE CELLS. Journal of Urology, 2013, 189, .	0.2	1
63	Impact of Parturition on Chemokine Homing Factor Expression in the Vaginal Distention Model of Stress Urinary Incontinence. Journal of Urology, 2013, 189, 1588-1594.	0.2	22
64	Animal models of female pelvic organ prolapse: lessons learned. Expert Review of Obstetrics and Gynecology, 2012, 7, 249-260.	0.4	76
65	1880 PATTERNS OF SACRAL NERVE STIMULATION LEAD FAILURES WITH ABNORMAL IMPEDANCE - WHAT CAN BE LEARNED?. Journal of Urology, 2012, 187, .	0.2	1
66	2137 INJURY RELATED STEM CELL HOMING CYTOKINES IN LYSYL OXIDASE LIKE-1 KNOCKOUT MICE: A PELVIC ORGAN PROLAPSE MODEL. Journal of Urology, 2012, 187, .	0.2	1
67	Stem cell therapy for voiding and erectile dysfunction. Nature Reviews Urology, 2012, 9, 435-447.	1.9	27
68	2138 IMPROVING VAGINAL SMOOTH MUSCLE ELASTIN DEPOSITION IN A GENETIC MODEL OF PELVIC ORGAN PROLAPSE: POTENTIAL PATHOPHYSIOLOGY-BASED THERAPY. Journal of Urology, 2012, 187, .	0.2	0
69	1384 THE ROLE OF SIMULATED HUMAN CHILDBIRTH INJURIES IN A LYSYL OXIDASE LIKE-1 KNOCKOUT MOUSE MODEL OF PELVIC ORGAN PROLAPSE, Journal of Urology, 2010, 183, .	0.2	0